Application No. 10/643,404 Amendment dated August 2, 2006 Reply to Office Action of April 20, 2006 Docket No.: 59753(48185)

RECEIVED
CENTRAL FAX CENTER

AUG - L LUU

AMENDMENTS TO THE CLAIMS

2

This listing of claims will replace all prior versions and listings of claims in the application.

(Currently amended) A method for prevention and/or therapy of arterial wall injury which is caused by coronary angioplasty or coronary-artery bypass graft (CABG), which comprises a step of administering 3-methyl-1-phenyl-2-pyrazolin-5-one the pyrazolone derivative represented by the following formula-(1) or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a preventively or therapeutically effective amount to mammals including humans[[:]].

$$\mathbb{R}^{2} \xrightarrow{\stackrel{\mathsf{N}}{\underset{-}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}{\underset{-}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{\mathsf{N}}}{\overset{N}}{\overset{\mathsf{N}}}$$

wherein R¹-represents a hydrogen atom, an aryl-group, a C₁₋₅-alkyl group, or a C₂₋₅ (total carbon number) alkoxylcarbonylalkyl group; R² represents a hydrogen atom, an aryloxy-group, an arylmercapto group, a C₁₋₅-alkyl group or a C₁₋₅-hydroxylalkyl group; or R¹-and R² are combined with each other-to-represent C₂₋₅-alkylene group; and R³ represents a hydrogen atom, a C₁₋₅-alkyl group, a G₃₋₇ eyeloalkyl group, a G₁₋₅-alkyl group, a benzyl group, a naphthyl group, a phenyl-group; or a phenyl-group substituted with the same or different 1 to 3 substituents selected from the group consisting of a C₁₋₅-alkyl group, a C₁₋₅-alkoxyl group, a C₁₋₅-alkyl group, a C₁₋₅-alkyl group, a C₁₋₅-alkyl group, a C₁₋₅-alkylmercapte group, a C₁₋₇-alkylmenton group, a C₂₋₅ (total carbon number) alkoxycarbonyl group, a C₁₋₅-alkylmercapte group, a C₁₋₇-alkylamino group, a C₂₋₅ (total carbon number) dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, and an acctanide group.

- 2. (Cancelled)
- (Cancelled)

Application No. 10/643,404 Amendment dated August 2, 2006 Reply to Office Action of April 20, 2006 Docket No.: 59753(48185)

4. (Currently amended) The method according to claim 1 or 2 wherein the arterial wall injury is restenosis or neointimal formation after perentaneous-transluminal-coronary angioplasty (PTGA)-or coronary-artery bypass graft (CABG).

3

5. (New) The method according to claim 1 or 4 wherein the coronary angioplasty is percutaneous transluminal coronary angioplasty (PCTA) or percutaneous coronary intervention (PCI).